| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:16818065 | IVR | 1 % | 1 % | Testicular atrophy | Reproductive endocrine-mediated perturbations |
| IVR | 1 % | 1 % | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 1 % | 1 % | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 % | 1 % | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| PMID:26922907 | IVTH | 0.00002 M | 0.00002 M | Affects blood-testis barrier (BTB) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00002 M | 0.00002 M | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| PMID:30391722 | IVTH | 0.000003 M | 0.000003 M | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | - | No significant effects observed | - | |
| IVTH | 0.000003 M | 0.000003 M | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | - | No significant effects observed | - | |
| IVTH | 0.000000001 M | - | No significant effects observed | - | |
| IVTH | 0.00000001 M | - | No significant effects observed | - | |
| PMID:32334352 | IVTH | 0.0001 - 0.0005 M | 0.0001 - 0.0005 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000025 - 0.0025 M | 0.0000025 - 0.0025 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0025 M | 0.0025 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:32682779 | IVTH | 0.00001 M | 0.00001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| PMID:36230992 | IVTH | 0.00001 M | 0.00001 M | Increased androstenedione levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0005 M | 0.0005 M | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0005 M | 0.0005 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:36607728 | IVR | 2 - 4 mg/kg/day | 2 - 4 mg/kg/day | Changes in morphology of pancreas | Metabolic endocrine-mediated perturbations |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 2 - 4 mg/kg/day | 2 - 4 mg/kg/day | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Increased Aspartate aminotransferase (AST) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 2 - 4 mg/kg/day | 2 - 4 mg/kg/day | Decreased pancreas weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 4 mg/kg/day | 1 - 4 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 2 - 4 mg/kg/day | 2 - 4 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:918990 | IVR | 800 mg/kg/day | 800 mg/kg/day | Testicular atrophy | Reproductive endocrine-mediated perturbations |
| IVR | 800 mg/kg/day | 800 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.